B. Escudier, J. Bellmunt, S. Negrier, E. Bajetta, B. Melichar et al., Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J Clin Oncol, vol.28, pp.2144-50, 2010.

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski et al., Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.27, pp.3584-90, 2009.

R. J. Motzer, B. Escudier, P. Tomczak, T. E. Hutson, M. D. Michaelson et al., Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, Lancet Oncol, vol.14, pp.552-62, 2013.

B. Escudier, C. Porta, P. Bono, T. Powles, T. Eisen et al., Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study, J Clin Oncol, vol.32, pp.1412-1420, 2014.

R. J. Motzer, T. E. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N Engl J Med, vol.369, pp.722-753, 2013.

T. K. Choueiri, B. Escudier, T. Powles, P. N. Mainwaring, B. I. Rini et al., Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1814-1837, 2015.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors, Cancer, vol.116, pp.4256-65, 2010.

M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, pp.883-92, 2012.

X. Yan, Y. Lin, D. Yang, Y. Shen, M. Yuan et al., A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth, Blood, vol.102, pp.184-91, 2003.

P. Zeng, H. Li, P. H. Lu, L. N. Zhou, M. Tang et al., Prognostic value of CD146 in solid tumor: A Systematic Review and Meta-analysis, Sci Rep, vol.7, p.4223, 2017.

Z. Wang and X. Yan, CD146, a multi-functional molecule beyond adhesion, Cancer Lett, vol.330, pp.150-62, 2013.

A. Ouhtit, R. L. Gaur, A. Elmageed, Z. Y. Fernando, A. Thouta et al., Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146, Biochim Biophys Acta, vol.1795, pp.130-136, 2009.

J. W. Liu, J. K. Nagpal, C. Jeronimo, J. E. Lee, H. R. Kim et al., Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer, Prostate, vol.68, pp.418-444, 2008.

T. Jiang, J. Zhuang, H. Duan, Y. Luo, Q. Zeng et al., CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis, Blood, vol.120, pp.2330-2339, 2012.

J. Wellbrock and W. Fiedler, CD146: a new partner for VEGFR2, Blood, vol.120, pp.2164-2169, 2012.

J. Stalin, K. Harhouri, L. Hubert, P. Garrigue, M. Nollet et al., Soluble CD146 boosts therapeutic effect of endothelial progenitors through proteolytic processing of short CD146 isoform, Cardiovasc Res, vol.111, pp.240-51, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01456844

E. M. Boneberg, H. Illges, D. F. Legler, and G. Furstenberger, Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process, Microvasc Res, vol.78, pp.325-356, 2009.

J. Stalin, M. Nollet, P. Garigue, S. Fernandez, L. Vivancos et al., Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors, Oncogene, vol.35, pp.5489-500, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01456904

M. Lv, Y. Shen, J. Yang, S. Li, B. Wang et al., Angiomotin Family Members: Oncogenes or Tumor Suppressors?, Int J Biol Sci, vol.13, pp.772-81, 2017.

B. Troyanovsky, T. Levchenko, G. Mansson, O. Matvijenko, and L. Holmgren, Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation, J Cell Biol, vol.152, pp.1247-54, 2001.

J. J. Adler, D. E. Johnson, B. L. Heller, L. R. Bringman, W. P. Ranahan et al., Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases, Proc Natl Acad Sci U S A, vol.110, pp.17368-73, 2013.

M. Ilie, E. Long, V. Hofman, E. Selva, C. Bonnetaud et al., Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer, Br J Cancer, vol.110, pp.1236-1279, 2014.

S. F. Kammerer-jacquet, A. Brunot, A. Pladys, G. Bouzille, J. Dagher et al., Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype, Clin Genitourin Cancer, vol.15, pp.1-7, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01470708

M. Dufies, S. Giuliano, D. Ambrosetti, A. Claren, P. D. Ndiaye et al., Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas, Cancer Res, vol.77, pp.1212-1238, 2017.

S. Negrier, G. Gravis, D. Perol, C. Chevreau, R. Delva et al., Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial, Lancet Oncol, vol.12, pp.673-80, 2011.

S. Giuliano, Y. Cormerais, M. Dufies, R. Grepin, P. Colosetti et al., Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux, Autophagy, vol.11, pp.1891-904, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02108861

R. Grepin, D. Ambrosetti, A. Marsaud, L. Gastaud, J. Amiel et al., The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma, PLoS ONE, vol.9, p.89449, 2014.

J. Gao, B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, vol.6, p.1, 2013.

E. Cerami, J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, vol.2, pp.401-405, 2012.

M. E. Gore, C. Szczylik, C. Porta, S. Bracarda, G. A. Bjarnason et al., Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma, Br J Cancer, vol.113, pp.12-21, 2015.

N. Bardin, M. Blot-chabaud, N. Despoix, A. Kebir, K. Harhouri et al., CD146 and its soluble form regulate monocyte transendothelial migration, Arterioscler Thromb Vasc Biol, vol.29, pp.746-53, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00428932

W. F. Liu, S. R. Ji, J. J. Sun, Y. Zhang, Z. Y. Liu et al., CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer, Int J Mol Sci, vol.13, pp.6399-406, 2012.

A. M. Imbert, C. Garulli, E. Choquet, M. Koubi, M. Aurrand-lions et al., CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition, PLoS One, vol.7, p.43752, 2012.